The review was conducted by Ayu Indriani Putri, Ari Sri Windyaswari, and Suci Nar Vikasari from the Faculty of Pharmacy at Universitas Jenderal Achmad Yani. Their findings are particularly relevant for tropical countries such as Indonesia, where venomous snakebites remain a major public health concern and access to treatment can be limited in rural communities.
Snakebites Remain a Global Health Challenge
Venomous snakebites affect millions of people worldwide every year and continue to cause substantial mortality, disability, and economic losses. The burden is especially severe in tropical and subtropical regions where people frequently work in agriculture, plantations, and environments close to snake habitats.
Indonesia is home to a wide variety of venomous snake species, including members of the Viperidae and Elapidae families. Encounters between humans and snakes are common in agricultural areas, increasing the risk of envenomation and serious medical complications.
According to the researchers, understanding how venom interacts with the immune system is becoming increasingly important because patient outcomes depend not only on the toxic effects of venom but also on how the body responds to it.
Reviewing the Latest Evidence
Rather than conducting laboratory experiments, the research team analyzed existing scientific literature published between 2020 and 2026.
The review examined 19 scientific studies, including:
- 7 preclinical studies
- 12 clinical studies
- Research sourced from PubMed, ScienceDirect, Google Scholar, and SINTA-indexed journals
The authors used a narrative synthesis approach to compare findings from multiple studies involving different snake species, venom compositions, antivenom products, and patient populations.
This method allowed the researchers to identify common patterns in how venom and antivenom influence immune responses.
Venom Does More Than Cause Toxicity
The review found that snake venom is a highly complex mixture of proteins, peptides, enzymes, and other biologically active molecules.
Key venom components include:
- Phospholipase A2 (PLA2)
- Snake venom metalloproteinases (SVMP)
- Serine proteases
- Neurotoxins
- Hemotoxins
- Cytotoxins
These substances directly damage tissues, disrupt blood clotting, impair nerve function, and can lead to organ failure in severe cases.
However, the researchers found that venom also activates the immune system. Once venom enters the body, immune cells release inflammatory molecules such as TNF-α, IL-1β, and IL-6. These substances increase blood vessel permeability and trigger swelling, inflammation, and tissue injury.
In severe envenomation, excessive immune activation can worsen clinical outcomes by contributing to coagulation disorders, vascular damage, tissue necrosis, and systemic complications.
The review identified different patterns among snake families. Viperid snakes, such as species from the Bothrops genus, commonly trigger bleeding disorders, thrombosis, inflammation, and tissue destruction. Elapid snakes, including cobras, primarily cause neurotoxic effects that can lead to paralysis and respiratory failure.
Antivenom Saves Lives but Can Trigger Immune Reactions
Despite these dangers, antivenom remains the most effective treatment available for venomous snakebites.
Antivenom works by binding to venom toxins and preventing them from interacting with tissues and organs. Clinical evidence reviewed in the study confirms that timely administration significantly reduces mortality and limits long-term complications.
Yet the review also highlights an important challenge: most antivenom products are derived from animal immunoglobulins, making them capable of triggering immune reactions in human patients.
Among the most frequently reported adverse reactions were:
- Urticaria (hives)
- Pruritus (itching)
- Bronchospasm
- Anaphylaxis
- Serum sickness
Immediate hypersensitivity reactions can develop within minutes or hours after treatment. In severe cases, anaphylaxis becomes a life-threatening medical emergency requiring rapid intervention.
Delayed immune reactions are also possible. Serum sickness may appear days after treatment due to immune-complex formation and can cause fever, rash, joint pain, and systemic inflammation.
The review found that reaction severity may be influenced by antivenom dose, administration frequency, product composition, and the patient's clinical condition.
Safer Antivenoms Are Under Development
The findings suggest that future improvements in snakebite treatment will depend not only on neutralizing toxins but also on reducing immune-related side effects.
Researchers worldwide are currently exploring several promising approaches:
- Purified antivenom formulations with fewer non-specific proteins
- Antibody fragments such as Fab and F(ab')₂
- Monoclonal antibodies
- Recombinant antibody technologies
- Adjunct therapies including anti-inflammatory agents and antioxidants
These innovations aim to maintain strong toxin-neutralizing capabilities while lowering the risk of hypersensitivity and serum sickness.
As the authors from Universitas Jenderal Achmad Yani explain, successful snakebite therapy depends on balancing two goals: eliminating venom toxins and managing the immune response generated by both venom and treatment.
Implications for Healthcare and Public Policy
The review has important implications for healthcare systems, particularly in countries with high snakebite incidence.
Healthcare facilities administering antivenom should be prepared to manage allergic reactions and anaphylaxis. The authors emphasize the importance of monitoring patients during and after treatment, as some immune complications may appear days later.
The findings also support efforts to:
- Improve access to high-quality antivenom
- Strengthen referral systems in rural areas
- Train healthcare workers in snakebite management
- Invest in next-generation antivenom technologies
Better understanding of venom-induced inflammation may also contribute to new therapeutic strategies that reduce tissue damage and improve recovery.
Expert Perspective
According to Ayu Indriani Putri, Ari Sri Windyaswari, and Suci Nar Vikasari of Universitas Jenderal Achmad Yani, venomous snakebite should be viewed as a complex interaction between toxins and the immune system. Their review indicates that venom activates inflammatory pathways that can worsen injury, while antivenom remains essential despite its potential to provoke immune reactions. This understanding can guide the development of safer and more effective treatments in the future.
0 Komentar